<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 07, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Among the causes of Cushing's syndrome are three rare types of nodular adrenocortical diseases that are usually bilateral (<a class="graphic graphic_table graphicRef50582" href="/d/graphic/50582.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Corticotropin (ACTH)-dependent bilateral macronodular adrenal hyperplasia, secondary to long-term adrenal stimulation in patients with Cushing's disease or ectopic ACTH syndrome. However, the adrenals rarely reach the massive size that can be seen with primary bilateral macronodular adrenal hyperplasia, and plasma ACTH may still be detectable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ACTH-independent micronodular adrenal hyperplasia and its most frequent variant, primary pigmented nodular adrenocortical disease (PPNAD), which may be sporadic or familial (as part of the Carney complex).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary bilateral macronodular adrenal hyperplasia (PBMAH), a disorder previously referred to as ACTH-independent bilateral macronodular adrenal hyperplasia (AIMAH).</p><p></p><p>PBMAH will be reviewed here. Other causes of Cushing's syndrome and PPNAD are discussed separately. (See  <a class="medical medical_review" href="/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/152.html" rel="external">"Cushing syndrome due to primary pigmented nodular adrenocortical disease"</a>.)</p><p class="headingAnchor" id="H1559178543"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Primary bilateral macronodular adrenal hyperplasia (PBMAH) has been described by various terms, including corticotropin (ACTH)-independent macronodular adrenal hyperplasia (AIMAH), primary macronodular adrenal hyperplasia (PMAH), massive macronodular adrenocortical disease (MMAD), autonomous macronodular adrenal hyperplasia (AMAH), ACTH-independent massive bilateral adrenal disease (AIMBAD), and "giant" or "huge" macronodular adrenal disease. However, we prefer and use primary bilateral macronodular adrenal hyperplasia (PBMAH) here.</p><p>PBMAH is an <strong>uncommon</strong> cause (&lt;2 percent) of endogenous Cushing's syndrome, characterized by enlarged adrenal glands containing multiple nonpigmented nodules that are greater than 10 mm in diameter but can be as large as 30 to 40 mm in diameter [<a href="#rid1">1</a>]. It can be diagnosed in patients with Cushing's syndrome but more often in those with incidentally found bilateral macronodular adrenals and modest secretion of cortisol who are between the ages of 40 and 60 years; as 10 to 15 percent of adrenal incidentalomas are bilateral, PBMAH is one of the causes of bilateral adrenal incidentalomas, but its precise prevalence has not been determined in population studies [<a href="#rid2">2</a>].</p><p>Aside from PBMAH, the differential diagnosis of bilateral adrenal incidentalomas includes disorders that are <strong>not</strong> associated with cortisol excess: bilateral adrenal adenomas, pheochromocytomas, metastasis, congenital adrenal hyperplasia (CAH), hemorrhage, lymphoma, and infiltrative and infectious diseases (<a class="graphic graphic_table graphicRef50582" href="/d/graphic/50582.html" rel="external">table 1</a>) [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma"</a>.)</p><p>In PBMAH, plasma ACTH levels become progressively suppressed when cortisol secretion is sufficiently elevated (increased urinary free cortisol [UFC] levels).</p><p>Treatment of PBMAH with overt Cushing's syndrome is usually surgical; bilateral adrenalectomy was previously utilized in most patients with PBMAH and severe Cushing's syndrome (UFC &gt;3 times upper limit of normal), but more recently, unilateral adrenalectomy was found to normalize UFC in a high proportion of patients with less severe Cushing's syndrome [<a href="#rid3">3</a>]. (See <a class="local">'Treatment'</a> below.)</p><p>In patients in whom aberrant hormone receptors have been identified, specific pharmacologic therapies have been utilized in selected cases as alternatives to adrenalectomy. (See <a class="local">'Pharmacologic therapy'</a> below.)</p><p class="headingAnchor" id="H668811581"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Aberrant hormone receptors, local production of corticotropin (ACTH) in adrenal tissues, and genetic mutations have been identified in the pathogenesis of PBMAH.</p><p class="headingAnchor" id="H668811619"><span class="h2">Aberrant hormone receptors</span><span class="headingEndMark"> — </span>The most prevalent abnormality in patients with PBMAH results from the aberrant adrenal expression of ectopic receptors or increased activity of eutopic peptide hormone receptors (<a class="graphic graphic_table graphicRef65003" href="/d/graphic/65003.html" rel="external">table 2</a>) [<a href="#rid4">4,5</a>]. Cortisol secretion becomes driven by a hormone that escapes cortisol-mediated feedback. In a series of patients with PBMAH (and mild or overt Cushing's syndrome) who were screened for aberrant receptors, more than 85 percent had at least one and usually several aberrant responses (most commonly to <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> and serotonin 5-hydroxytryptamine 4 [5-HT4] agonists) [<a href="#rid6">6-10</a>]. Examples of aberrant receptors include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">Vasopressin</a> – Vasopressin-responsive Cushing's syndrome is the most frequent aberrant stimulator of cortisol secretion in patients with PBMAH. In these patients, cortisol secretion increases with upright posture or other physiological stimuli of endogenous vasopressin, such as hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> infusion [<a href="#rid4">4,5,8,11-18</a>]. In most, cortisol secretion was regulated by the V1-vasopressin receptor (no stimulation by <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>, a preferential V2 receptor agonist), expressed at either normal or high levels.</p><p></p><p class="bulletIndent1">The V1-vasopressin receptor is normally expressed in the adrenal cortex but is not a major regulator of steroidogenesis. In patients with PBMAH, the exaggerated steroidogenic responses to <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> are secondary to the increased activity and/or expression of a "eutopic" receptor-effector system.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-adrenergic</strong> – PBMAH and Cushing's syndrome have been reported in patients with aberrant adrenal expression of beta-adrenergic receptors. Plasma cortisol and aldosterone levels increase in response to elevations in endogenous catecholamines that occur with upright posture, insulin-induced hypoglycemia, and exercise [<a href="#rid19">19</a>]. <a class="drug drug_general" data-topicid="8578" href="/d/drug information/8578.html" rel="external">Isoproterenol</a> infusion stimulates cortisol and aldosterone secretion, and <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> blocks this effect and reduces basal cortisol secretion with long-term control of hypercortisolism [<a href="#rid20">20</a>]. These effects were not seen in normal subjects. Similar findings have been reported in other patients with PBMAH [<a href="#rid8">8,16,21</a>]. High-affinity binding sites compatible with beta-1- or beta-2-adrenergic receptors were efficiently coupled to steroidogenesis in the adrenal tissues in these patients, but not in controls, indicating the ectopic nature of this receptor [<a href="#rid16">16,19,21</a>].</p><p></p><p class="bulletIndent1">The combined presence of adrenal beta-adrenergic receptor and V1-vasopressin receptor has been observed in other patients with PBMAH [<a href="#rid8">8,16,19,21</a>]. The combined overexpression of beta-2-adrenoreceptor, serotonin 5-HT4 receptor, and V1-vasopressin receptor also was demonstrated [<a href="#rid20">20,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LH/hCG</strong> – Hypercortisolism due to aberrant luteinizing hormone (LH)/human chorionic gonadotropin (hCG) receptors was first identified in a woman with history of transient Cushing's syndrome during sequential pregnancies; however, persistent Cushing's syndrome and PBMAH developed only after the postmenopausal sustained increase of LH secretion [<a href="#rid23">23</a>]. Administration of the long-acting gonadotropin-releasing hormone (GnRH) agonist, <a class="drug drug_general" data-topicid="9549" href="/d/drug information/9549.html" rel="external">leuprolide</a> acetate, resulted in suppression of endogenous LH and normalization of cortisol production [<a href="#rid23">23</a>]. In a 22-year-old woman who presented with transient bilateral adrenal hyperplasia and severe Cushing's syndrome during two pregnancies, in vivo and in vitro studies in resected adrenals demonstrated that hCG could stimulate the transformation of progenitor subcapsular adrenal LH/hCG receptor-expressing cells into hyperplastic adrenocortical cells, increasing their steroidogenesis under hCG stimulation [<a href="#rid24">24</a>]. In a 59-year-old woman with androgen-secreting PBMAH resulting in virilization, aberrant LH/hCG receptors were identified in one resected adrenal. Suppression of endogenous LH with leuprolide acetate normalized androgen secretion from the contralateral adrenal, thereby avoiding bilateral adrenalectomy [<a href="#rid25">25</a>]. A 64-year-old woman with PBMAH expressing LH/hCG receptor and aromatase presented with mastodynia, which regressed by long-term therapy with leuprolide acetate [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">In nonpregnant women, most cases of Cushing's syndrome in nonpregnant women are due to an ACTH-secreting pituitary adenoma (Cushing's disease). In contrast, the frequency of ACTH-independent cases is considerably higher in pregnant women with Cushing's syndrome. It seems likely that LH/hCG receptors on the adrenal are at least in part responsible for this phenomenon. (See  <a class="medical medical_review" href="/d/html/139.html" rel="external">"Diagnosis and management of Cushing syndrome during pregnancy", section on 'Causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serotonin</strong> – Other cases of aberrant receptors for LH/hCG or serotonin, either alone or in combination, have been reported [<a href="#rid11">11,12,27</a>]. In one of the patients described above [<a href="#rid23">23</a>], serotonin 5-HT4 receptor agonists, <a class="drug drug_general" data-topicid="9269" href="/d/drug information/9269.html" rel="external">cisapride</a> and <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>, also stimulated plasma cortisol.</p><p></p><p class="bulletIndent1">Following the initial description of combined aberrant LH and serotonin 5-HT4 receptors in PBMAH, several other patients were found to have increased secretion of cortisol following stimulation with <a class="drug drug_general" data-topicid="9269" href="/d/drug information/9269.html" rel="external">cisapride</a>, <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>, or tegaserod [<a href="#rid11">11,12,18,27-30</a>]. In most cases, a large overexpression of 5-HT4 receptor was found in the adrenals [<a href="#rid31">31-33</a>]. The ectopic expression and function of serotonin 5-hydroxytryptamine 7 (5-HT7) receptor was identified in a patient with serotonin-responsive PBMAH and Cushing's syndrome [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GIP</strong> – The ectopic expression of glucose-dependent insulinotropic peptide (also known as gastric inhibitory polypeptide [GIP]) receptor in zona fasciculata cells causes <strong>"food-dependent" cortisol production</strong>. Plasma cortisol levels may be relatively low during fasting and increase transiently following meals [<a href="#rid34">34-36</a>]. GIP-dependent Cushing's syndrome has been reported in approximately 20 patients with PBMAH [<a href="#rid34">34-41</a>]. GIP receptors are not expressed in the normal adult or fetal zona fasciculata [<a href="#rid36">36-39,42</a>]. GIP receptor overexpression in PBMAH occurs from a single allele of the GIPR gene (ch 19q) and, in some cases of unilateral adenoma or PBMAH, resulted from chromosome 19q region gene duplication and rearrangement [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1">The adrenal nodules in some patients with GIP-dependent PBMAH can progress asynchronously, first in one adrenal, later in the other [<a href="#rid39">39</a>]; in one report, the adrenal adjacent to the macronodules was not atrophic but showed diffuse adrenal hyperplasia with ectopic GIP receptor expression [<a href="#rid39">39</a>], suggesting that larger nodules were the result of secondary clonal proliferation events [<a href="#rid44">44</a>]. In one case, GIP-dependent PBMAH zones were mixed with bilateral myelolipomas [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1">Other reported cases include patients with combined aberrant expression of GIP receptor and LH/hCG receptor [<a href="#rid12">12,45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiotensin</strong> – In a patient with PBMAH and a large increase in plasma aldosterone and cortisol levels during upright posture, short-term oral administration of the angiotensin II receptor antagonist <a class="drug drug_general" data-topicid="8670" href="/d/drug information/8670.html" rel="external">candesartan</a> completely inhibited the elevation in cortisol and aldosterone [<a href="#rid46">46</a>]. In vitro stimulation of cortisol secretion by angiotensin II was also found in patients with PBMAH and Cushing's syndrome who had increases in cortisol levels with upright posture [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other receptors</strong> – In a study that looked to identify novel abnormally expressed G-protein-coupled receptors (GPCRs) in patients with PBMAH, several new aberrant receptor genes were identified, one of which (the alpha-2A-adrenergic receptor [<em>ADRA2A</em>], highly expressed in 13 of 18 BMAHs) may be a potential target for pharmacologic treatment of Cushing's syndrome due to PBMAH [<a href="#rid47">47</a>]. <a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">Clonidine</a> (an <em>ADRA2A</em> agonist) administration resulted in an increase in cortisol production; the increase could be blocked by an <em>ADRA2A</em> antagonist, yohimbine. In other patients, the administration of <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> increased plasma cortisol, while <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> inhibited plasma cortisol in patients with PBMAH and mild Cushing's syndrome [<a href="#rid6">6</a>]. (See <a class="local">'Screening for aberrant receptors'</a> below.)</p><p></p><p class="headingAnchor" id="H668811725"><span class="h2">Paracrine secretion of ACTH</span><span class="headingEndMark"> — </span>The hypercortisolism associated with primary PBMAH was previously considered to be corticotropin (ACTH) independent. However, it appears that cortisol secretion in PBMAH is at least partially regulated by intra-adrenal ACTH, which is produced by steroidogenic cells in the hyperplastic adrenals [<a href="#rid48">48,49</a>].</p><p>In a report of 30 patients with PBMAH, proopiomelanocortin (POMC) mRNA was detected in all 26 PBMAH adrenal gland samples analyzed; moderate/intense immunostaining for ACTH was detectable in clusters of steroidogenic cells in most samples [<a href="#rid49">49</a>]. Conversely, no ACTH staining was present in normal adrenal cortex or cortisol-secreting adenomas [<a href="#rid49">49</a>]. ACTH secretion was also confirmed by the demonstration of an ACTH gradient in adrenal vein sampling in two PBMAH patients, but ACTH plasma levels remained low.</p><p>In vitro, adrenal ACTH secretion was not regulated by corticotropin-releasing hormone (CRH), <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, or <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a>. In contrast, tissues that expressed aberrant GPCRs released ACTH and cortisol during perifusion with GIP, serotonin, or hCG. ACTH receptor antagonists inhibited cortisol secretion by 40 percent in these tissues. Thus, in vitro studies show that cortisol production is apparently controlled both by aberrant GPCR and ACTH produced within the adrenocortical tissue, amplifying the effect of the aberrant receptors' ligands. The ectopic expression of POMC and synthesis of ACTH has been confirmed in PBMAH tissues in primary cultures; ACTH synthesis and aberrant GPCR were maintained in primary cultures of cells with or without <em>ARMC5</em> (armadillo repeat-containing 5 gene) mutations [<a href="#rid50">50</a>]. The confirmation that paracrine adrenal production of ACTH and other peptides is central in cortisol regulation of PBMAH will necessitate confirmation by other groups and in vivo demonstration that inhibition of adrenal ACTH and other receptors reverses hypercortisolism in affected patients [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H668811731"><span class="h2">Genetic causes</span><span class="headingEndMark"> — </span>Several molecular causes have been identified in the pathogenesis of primary PBMAH, indicating that it is a heterogeneous disease [<a href="#rid7">7</a>]. Most cases of PBMAH were thought to be sporadic [<a href="#rid51">51-54</a>]. However, there are now several reports of familial cases of PBMAH whose presentation suggests autosomal dominant transmission [<a href="#rid16">16-18,55-60</a>].</p><p>In familial cases of PBMAH, a number of aberrant hormone receptors, but no genetic abnormality, had been identified in individual families investigated initially, including V1-V2- and V3-vasopressin [<a href="#rid17">17</a>], beta-adrenergic [<a href="#rid58">58</a>], combined V1-vasopressin and beta-adrenergic [<a href="#rid16">16,20</a>], and combined 5-HT4 and V1-V2-vasopressin [<a href="#rid18">18</a>] (see <a class="local">'Aberrant hormone receptors'</a> above). Several genetic abnormalities have now been identified in PBMAH kindreds.</p><p class="bulletIndent1"><span class="glyph">●</span>Germline mutations of <em>ARMC5</em> are found in approximately 25 percent of apparently sporadic PBMAH patients [<a href="#rid61">61-65</a>]. <em>ARMC5</em> behaves as a tumor suppressor gene, and different somatic <em>ARMC5</em> mutations or deletions were found in each adrenal nodule examined and appeared to accelerate the proliferation of affected cells [<a href="#rid61">61,66,67</a>]. In two studies, a high percentage of first-degree relatives of the probands carried a germline <em>ARMC5</em> mutation and unsuspected PBMAH [<a href="#rid61">61,63</a>].</p><p></p><p class="bulletIndent1">In one large family, which included 22 mutation carriers, two had Cushing's syndrome, 17 had only mild cortisol excess, while three patients aged 25, 29, or 76 years were silent carriers; in 6 of 22, only one adrenal was enlarged, suggesting variable penetrance of the <em>ARMC5</em> mutation [<a href="#rid63">63</a>]. A high prevalence of biallelic <em>ARMC </em>mutations were identified in other families with PBMAH [<a href="#rid20">20,68-71</a>]. The relationship between <em>ARMC5</em> mutations and aberrant receptors or ACTH expression has not been studied in detail yet; no <em>ARMC5</em> mutation carriers had GIP-dependent Cushing's syndrome, but some had aberrant regulation by <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>, beta-adrenergic, and serotonin agonists [<a href="#rid20">20,64,69</a>]. Somatic mutation of <em>ARMC5 </em>was also found in meningiomas, which can occur in familial PBMAH, suggesting that other tumors could result from mutations of the <em>ARMC5</em> tumor suppressor gene (which is expressed in several human tissues) [<a href="#rid17">17,40,63,69</a>]. Two models of <em>ARMC5</em> gene knockout in mice should allow better understanding of the mechanisms of its mutations in adrenal proliferation and function [<a href="#rid72">72,73</a>].</p><p></p><p class="bulletIndent1">However, in patients with bilateral adrenal incidentalomas, germline <em>ARMC5</em> mutations are rarely found [<a href="#rid74">74,75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cushing's syndrome associated with McCune-Albright syndrome (MAS) is a rare variant of PBMAH that presents in infancy or childhood. MAS is a sporadic disease characterized by polyostotic fibrous dysplasia with café au lait spots, sexual precocity, and other endocrine and nonendocrine disorders [<a href="#rid31">31,76</a>]. An activating somatic of the alpha-subunit stimulatory guanine nucleotide-binding protein, Gs, occurs in some adrenal cells in a mosaic pattern, which leads to the formation of adrenal nodules [<a href="#rid77">77,78</a>]. Activating mutations of Gs alpha have been occasionally found in the PBMAH nodules of pediatric or adult patients without any other features of MAS [<a href="#rid78">78,79</a>]. (See  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty", section on 'McCune-Albright syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral adrenal nodules also have been described as part of multiple endocrine neoplasia syndrome type 1 (MEN1). A retrospective analysis of 715 MEN1 patients found the presence of adrenal lesions in 20 percent, and of those with lesions &gt;1 cm, 12.9 percent had bilateral lesions without further evaluation of how many were PBMAH; most unilateral or bilateral tumors were nonfunctional, but primary aldosteronism was more frequent than in a control group of adrenal incidentalomas without MEN1 [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PBMAH or adrenal nodules have been reported in patients with familial adenomatous polyposis and a mutation in the adenomatous polyposis coli (<em>APC</em>) gene [<a href="#rid7">7,81</a>] and with hereditary leiomyomatosis and renal cell cancer disorders due to mutations in the fumarate hydratase (<em>FH</em>) gene [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/d/html/2593.html" rel="external">"Clinical manifestations and diagnosis of familial adenomatous polyposis"</a> and  <a class="medical medical_review" href="/d/html/2948.html" rel="external">"Hereditary kidney cancer syndromes", section on 'Hereditary leiomyomatosis and renal cell cancer syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Missense germline mutations in phosphodiesterase 11A isoform 4 gene (<em>PDE11A</em>) have been identified initially in kindreds with nonpigmented micronodular hyperplasia but have now been found at higher frequency in patients with various adrenocortical tumors, including PBMAH [<a href="#rid83">83</a>]. As noted above, PBMAH is thus probably genetically heterogeneous, with occasional cases that occur in association with other syndromes [<a href="#rid7">7,32,81,82,84,85</a>], and this has been reviewed in further detail [<a href="#rid86">86-88</a>]. (See  <a class="medical medical_review" href="/d/html/152.html" rel="external">"Cushing syndrome due to primary pigmented nodular adrenocortical disease"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL FEATURES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Later age at onset</strong> – Patients with PBMAH and Cushing's syndrome typically present in the fifth and sixth decades [<a href="#rid51">51-54</a>], a later age of onset compared with unilateral adrenal cortisol-producing adenomas, primary pigmented nodular adrenocortical disease (PPNAD), or pituitary corticotroph adenomas (Cushing's disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilateral adrenal incidentalomas, mild cortisol production</strong> – The majority of patients with PBMAH have only mild cortisol production and present with bilateral adrenal incidentalomas [<a href="#rid1">1</a>]. In these patients, no symptoms of Cushing's syndrome may be present, and the nodular adrenals are identified when abdominal imaging (ultrasound, computed tomography [CT] scan, or magnetic resonance imaging [MRI]) are performed for unrelated reasons.</p><p></p><p class="bulletIndent1">In patients in whom cortisol secretion is sufficient to produce mild or overt Cushing's syndrome, the symptoms and signs are similar to other etiologies of primary adrenal Cushing's syndrome. (See  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enlarged adrenals</strong> – Primary PBMAH is associated with adrenal glands weighing from 25 to 500 g (normal range 4 to 6 g per adrenal) that contain multiple nonpigmented nodules greater than 10 mm in diameter [<a href="#rid51">51-53</a>]. The enlargement of the adrenal glands is not associated with pain. The nodules appear to be typical benign adrenal nodules, but the internodular cortex may be either hyperplastic (in most cases) or atrophic. PBMAH may present with asynchronous nodular hyperplasia in one gland and later in the contralateral gland [<a href="#rid1">1,39,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PBMAH with overt Cushing's syndrome</strong> – Laboratory findings are similar to those seen in corticotropin (ACTH)-independent Cushing's syndrome with unilateral tumors and include the following (see  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased serum and 24-hour urinary free cortisol (UFC) and low to undetectable plasma ACTH (&lt;10 pg/mL [&lt;2 pmol/L]) in the basal state and after administration of corticotropin-releasing hormone (CRH) [<a href="#rid51">51-54</a>]. (Cut-offs vary depending on normal range of ACTH assays.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased late-night salivary cortisol levels.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum dehydroepiandrosterone sulfate (DHEAS) levels are usually suppressed as ACTH levels become suppressed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cortisol production is not suppressed by low- or high-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> tests.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An exception to this general pattern occurs in patients with gastric inhibitory polypeptide (GIP)-dependent Cushing's syndrome in whom cortisol hypersecretion occurs in response to meals and serum cortisol may be low in the fasting state [<a href="#rid34">34,35</a>]. (See <a class="local">'Aberrant hormone receptors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Steroid hormone synthesis is relatively inefficient in PBMAH, as a consequence of decreased steroidogenic enzymatic activity resulting frequently in elevated 17-hydroxyprogesterone levels basally or after stimulation with ACTH [<a href="#rid6">6,11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Co-secretion of serum aldosterone, 18-hydroxycorticosterone, corticosterone, and <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> may cause hypertension, primary aldosteronism, or feminization in the rare patients in whom they are increased [<a href="#rid26">26,89,90</a>].</p><p></p><p class="headingAnchor" id="H890902628"><span class="h1">INITIAL EVALUATION</span></p><p class="headingAnchor" id="H2008322133"><span class="h2">Bilateral incidentalomas</span></p><p class="headingAnchor" id="H2547241116"><span class="h3">Hormonal hypersecretion</span><span class="headingEndMark"> — </span>Most patients with PBMAH present with bilateral incidentalomas and mild cortisol excess (see <a class="local">'Clinical features'</a> above). Their initial evaluation is similar to that for a unilateral incidentaloma and includes tests to look for hormonal hypersecretion, most importantly, the degree of cortisol excess (Cushing's syndrome), but also catecholamine and aldosterone excess (eg, pheochromocytomas and aldosteronomas) (see  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Evaluation for hormonal secretion'</a> and  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Subclinical Cushing syndrome'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>1 mg overnight <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test</p><p class="bulletIndent1"><span class="glyph">●</span>24-hour urinary metanephrine or plasma free metanephrine levels</p><p class="bulletIndent1"><span class="glyph">●</span>Aldosterone/renin ratio (only if the patient has hypertension)</p><p></p><p>In <strong>contrast</strong> with unilateral incidentalomas, the following additional testing is also indicated in patients with bilateral macronodules, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Early-morning cortisol and corticotropin (ACTH) levels to rule out primary adrenal insufficiency from bilateral infiltrative/infectious/metastatic diseases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A serum 17-hydroxyprogesterone level is measured to rule out nonclassic congenital adrenal hyperplasia (NCCAH) due to 21-hydroxylase deficiency, which may sometimes present as silent bilateral adrenal incidentalomas. (See  <a class="medical medical_review" href="/d/html/147.html" rel="external">"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on '17-hydroxyprogesterone'</a>.)</p><p></p><p>As noted, the majority of patients with primary PBMAH have no or mild clinical features of<strong> </strong>Cushing's syndrome. They have normal urinary free cortisol (UFC), detectable ACTH levels still responsive to corticotropin-releasing hormone (CRH), but with subnormal suppression of plasma cortisol following <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid4">4,5,11</a>]. In these patients, low- or high-dose dexamethasone will produce partial suppression of cortisol but not to &lt;1.8 mcg/dL (50 nmol/L) in the morning following nighttime 1 mg dexamethasone administration [<a href="#rid4">4,9,11</a>].</p><p>After a nighttime dose of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (1 mg), a range of morning cortisol levels from 1.8 mcg/dL (50 nmol/L) to an intermediate level of 5 mcg/dL (140 nmol/L) to &gt;10 mcg/dL (280 nmol/L) can be seen.</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with serum cortisol concentrations &gt;10 mcg/dL typically have elevated UFC, suppressed ACTH, and progressive clinical signs of Cushing's syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those between 1.8 and 10 mcg/dL may have minimal clinical manifestations, but this is probably also affected by various factors, including duration of disease and glucocorticoid receptor sensitivity.</p><p></p><p>One case of massive PBMAH in a male patient was found to produce large amounts of adrenal androgens (dehydroepiandrosterone [DHEA], dehydroepiandrosterone sulfate [DHEAS]) without any cortisol excess (ACTH not suppressed) or clinical symptoms and was detected only as bilateral incidentaloma [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H4093639569"><span class="h3">Degree of cortisol excess</span><span class="headingEndMark"> — </span>So, if the initial screening with 1 mg overnight <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> does not suppress cortisol to &lt;1.8 mcg/dL (50 nmol/L), we perform the following additional tests to evaluate the degree of cortisol oversecretion:</p><p class="bulletIndent1"><span class="glyph">●</span>24-hour UFC <strong>(twice)</strong>. (See  <a class="medical medical_review" href="/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome", section on '24-hour urinary cortisol excretion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Salivary late-night cortisol <strong>(twice)</strong>. This is a screening test for Cushing's syndrome and is described in detail separately. (See  <a class="medical medical_review" href="/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome", section on 'Bedtime salivary cortisol'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fasting ACTH (if not done previously). (See  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aldosterone-to-renin ratio is performed to detect mild aldosterone excess, even in the absence of hypertension, when UFC is elevated and ACTH suppressed. Co-secretion of aldosterone can be seen in PBMAH. (See <a class="local">'Aberrant hormone receptors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional blood tests such as DHEAS levels, total <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a>, sex hormone-binding globulin (SHBG), and estradiol may be measured depending upon the clinical findings (eg, virilization in women, hypogonadism or gynecomastia in men, and patients with elevated UFC and suppressed ACTH).</p><p></p><p class="headingAnchor" id="H968511918"><span class="h2">Imaging findings</span><span class="headingEndMark"> — </span>The results of adrenal computed tomography (CT) and magnetic resonance imaging (MRI) are variable, ranging from apparently unilateral nodules to massive bilateral enlargement [<a href="#rid39">39,51-54,92</a>]. Multiple nodules may be seen that are greater than 10 mm in diameter, but can be as large as 30 to 40 mm in diameter [<a href="#rid1">1</a>] (55 mm in one study [<a href="#rid92">92</a>]). However, in some cases, diffuse enlargement of both adrenals can be present without distinct nodules. In one series of 12 patients, 11 had enlarged multinodular glands; 9 patients underwent pituitary CT or MRI, and all were normal [<a href="#rid92">92</a>].</p><p>Adrenal scintigraphy with iodine-131 (131-I)-labeled cholesterol showed bilateral uptake in four of five patients in one report [<a href="#rid92">92</a>]. Although not widely available, this imaging technique could help identify which gland to remove if one chooses unilateral adrenalectomy. A preliminary study indicated increased fluorodeoxyglucose-positron emission tomography (FDG-PET) signal in PBMAH tissues despite absence of malignancy; the frequency of such increased FDG-signal uptake remains to be confirmed in larger cohorts [<a href="#rid93">93,94</a>].</p><p class="headingAnchor" id="H15"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of PBMAH is made in patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Overt Cushing's syndrome and suppressed corticotropin (ACTH) levels in whom bilaterally enlarged nodular adrenals are found at abdominal computed tomography (CT) scan (a minority of cases).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Incidentally found bilateral adrenal hyperplasia with several macronodules in whom a subnormal suppression of cortisol is found (&gt;1.8 mcg/dL or &gt;50 nmol/L) following 1 mg overnight <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test (the majority of cases).</p><p></p><p class="bulletIndent1">However, in individuals with single nodules in each adrenal and subclinical cortisol secretion, the diagnosis could be bilateral adenomas or an early phase of PBMAH.</p><p></p><p class="headingAnchor" id="H968511870"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Primary PBMAH, a pituitary ACTH-independent form of Cushing's syndrome, must be distinguished from (<a class="graphic graphic_table graphicRef50582" href="/d/graphic/50582.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral cortisol-producing adrenal adenomas</p><p class="bulletIndent1"><span class="glyph">●</span>Primary pigmented nodular adrenocortical disease (PPNAD)</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary ACTH-dependent macronodular adrenal hyperplasia (Cushing's disease or ectopic ACTH secretion)</p><p></p><p>Features that can help distinguish between these disorders include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary PBMAH versus secondary ACTH-dependent macronodular hyperplasias – Measure plasma ACTH:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Plasma ACTH is suppressed by excess cortisol in PBMAH (&lt;10 pg/mL [&lt;2 pmol/L]). In contrast, ACTH is inappropriately normal or slightly high in ACTH-dependent macronodular hyperplasia (≥15 pg/mL [3.3 pmol/L]). (See  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rare patients with ACTH-dependent hyperplasia have low but consistently detectable plasma ACTH concentrations (≤10 pg/mL [2 pmol/L]), presumably due to its suppression by some of their adrenal nodules, which have acquired the capacity to secrete cortisol constitutively by unidentified mechanisms [<a href="#rid95">95,96</a>]. (See  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among the different primary adrenal sources of Cushing's syndrome, there are several features that are suggestive of PBMAH:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients with overt Cushing's syndrome due to PBMAH present in the fifth and sixth decades [<a href="#rid51">51-54</a>], a later age of onset compared with unilateral cortisol-producing adenomas or PPNAD.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Size of adrenal gland nodules usually clearly distinguish PPNAD (micronodular) from PBMAH (macronodular).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>While the typical laboratory findings of PBMAH with overt Cushing's syndrome include high fasting serum and urinary cortisol and suppressed plasma ACTH and dehydroepiandrosterone sulfate (DHEAS) concentrations [<a href="#rid51">51-54</a>], an exception to this general pattern occurs in patients with PBMAH and gastric inhibitory polypeptide (GIP)-dependent Cushing's syndrome, in whom cortisol hypersecretion occurs in response to meals [<a href="#rid34">34,35</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Metastatic or infiltrative adrenal diseases – In PBMAH, the increase in cortisol following administration of exogenous ACTH is greater than in normal adrenals and reflects the large adrenal cell mass [<a href="#rid6">6,8</a>]. This biochemical finding can be useful in distinguishing PBMAH from other causes of bilaterally enlarged adrenals such as metastatic or infiltrative diseases, where steroidogenic response to ACTH administration is decreased. In PPNAD, cortisol response is usually limited following exogenous ACTH stimulation.</p><p></p><p class="headingAnchor" id="H968512065"><span class="h1">FURTHER EVALUATION AFTER DIAGNOSIS</span><span class="headingEndMark"> — </span>Further evaluation is needed in patients diagnosed with PBMAH and overt or mild Cushing's syndrome.</p><p class="headingAnchor" id="H890902871"><span class="h2">Metabolic consequences of hypercortisolism</span><span class="headingEndMark"> — </span>Once the diagnosis of PBMAH is established, further evaluation is necessary to look for potential metabolic consequences of cortisol excess. Patients should undergo evaluation for<strong> </strong>glucose intolerance and type 2 diabetes (fasting glucose, glycated hemoglobin [A1C] levels, or oral glucose tolerance test [OGTT]), hypertension (including 24-hour monitoring if necessary), coronary heart disease, and bone health (bone mineral density and vertebral fracture assessment).</p><p class="headingAnchor" id="H1559179074"><span class="h2">Screening for aberrant receptors</span><span class="headingEndMark"> — </span>In our center and several other academic centers [<a href="#rid1">1,4-9,11,13-19,21-23,25,27-30,34-40,45</a>], we suggest that patients with PBMAH and clinical or mild Cushing's syndrome undergo screening for aberrant receptors as this may change the therapeutic strategy (<a class="graphic graphic_table graphicRef65003" href="/d/graphic/65003.html" rel="external">table 2</a>). Protocols have been developed to systematically evaluate for these aberrant receptors (<a class="graphic graphic_table graphicRef65003" href="/d/graphic/65003.html" rel="external">table 2</a>) [<a href="#rid4">4-9,12</a>].</p><p>The strategy is to examine whether cortisol or other steroids change in response to physiological (upright posture, mixed meals) and pharmacologic (gonadotropin-releasing hormone [GnRH], <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>, <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>, <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>) tests that modulate the levels of ligands for the potential aberrant receptors. Of note, thyrotropin-releasing hormone (TRH) testing has rarely yielded aberrant responses, and TRH is not widely available. We therefore do <strong>not</strong> consider TRH testing to be necessary when screening for aberrant receptors.</p><p>Another group has suggested restricting tests to those for which a therapy is possible, ie, mixed meal, posture test, and luteinizing hormone-releasing hormone (LHRH) test [<a href="#rid97">97</a>]. As this disease is relatively rare, we recommend that patients be referred to expert centers that can offer detailed investigation capacity.</p><p class="headingAnchor" id="H18"><span class="h2">Screening family members</span><span class="headingEndMark"> — </span>First-degree relatives (&gt;25 years of age) of patients with PBMAH who do not carry armadillo repeat-containing 5 (<em>ARMC5</em>) gene mutations should be screened for PBMAH by first looking for evidence of hypercortisolism. This can be done with an overnight 1 mg <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> test; those who do not suppress their plasma cortisol on the following morning below 1.8 mcg/dL (50 nmol/L) should undergo adrenal computed tomography (CT) scan to look for possible features of PBMAH (adrenal nodules, bilateral enlargement). (See  <a class="medical medical_review" href="/d/html/160.html" rel="external">"Dexamethasone suppression tests", section on 'Overnight screening test'</a> and <a class="local">'Imaging findings'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Family members who are found to have PBMAH should undergo detailed biochemical and clinical investigation described above and targeted evaluation for the aberrant hormone receptors that were found in the initial case if it can lead to specific targeted medical therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with PBMAH associated with other genetic causes such as multiple endocrine neoplasia syndrome type 1 (MEN1) or familial adenomatous polyposis should undergo the recommended evaluation/screening for those disorders. (See  <a class="medical medical_review" href="/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Monitoring for MEN1-associated tumors'</a> and  <a class="medical medical_review" href="/d/html/2592.html" rel="external">"Familial adenomatous polyposis: Screening and management of patients and families"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The search for germline <em>ARMC5</em> mutations (and possibly other genes as more are identified) now allows familial screening through a simple blood test and identify who should undergo further evaluations [<a href="#rid48">48,61</a>]. (See <a class="local">'Genetic causes'</a> above.)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The initial patients identified with PBMAH were evaluated because of severe Cushing's syndrome and underwent bilateral adrenalectomy. However, considering the wide range of clinical presentations from asymptomatic bilateral incidentaloma cases to overt Cushing's syndrome, we currently recommend the following approaches based on severity of cortisol excess:</p><p class="headingAnchor" id="H753019922"><span class="h2">Patients without aberrant receptors</span></p><p class="headingAnchor" id="H2152867790"><span class="h3">Overt Cushing's syndrome</span></p><p class="headingAnchor" id="H694974059"><span class="h4">Bilateral adrenalectomy</span><span class="headingEndMark"> — </span>We suggest bilateral surgical adrenalectomy for patients with PBMAH, equally enlarged macronodular adrenals, and clinically severe Cushing's syndrome (elevated urinary free cortisol [UFC] &gt;3 times above upper limit of normal in repeated samples) who have <strong>no</strong> evidence of aberrant receptors that would be amenable to specific medical therapy. Surgical bilateral adrenalectomy is uniformly effective in these patients. Unilateral adrenalectomy is sometimes performed if one adrenal is much larger than the other as this could also result in normalization of UFC without permanent adrenal insufficiency [<a href="#rid3">3,98</a>].</p><p>We agree with the Endocrine Society guidelines and suggest thromboprophylaxis in patients with overt Cushing's syndrome going to surgery because of their high risk of thromboembolism [<a href="#rid99">99</a>] (see  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome", section on 'Thromboembolic events'</a>). Post-adrenalectomy, these patients will require lifetime glucocorticoid and mineralocorticoid replacement but are <strong>not</strong> at risk for Nelson syndrome (corticotroph tumor progression), because the pituitary is intrinsically normal. Therefore, pituitary radiation to prevent Nelson syndrome is unnecessary. (See  <a class="medical medical_review" href="/d/html/16322.html" rel="external">"Persistent or recurrent Cushing disease: Surgical adrenalectomy", section on 'Nelson syndrome'</a>.)</p><p>Adrenal enzyme inhibitors are sometimes given to patients with overt Cushing's syndrome to control cortisol secretion before surgery, particularly if surgery needs to be delayed for some underlying condition such as infection, recent cerebrovascular or coronary event, or pulmonary emboli [<a href="#rid100">100,101</a>]. (See  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)", section on 'Initial therapy'</a>.)</p><p>Surgical adrenalectomy, including surgical approach and postoperative hormone replacement, is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/16322.html" rel="external">"Persistent or recurrent Cushing disease: Surgical adrenalectomy"</a> and  <a class="medical medical_review" href="/d/html/15027.html" rel="external">"Adrenalectomy techniques"</a>.)</p><p class="headingAnchor" id="H2441790401"><span class="h3">Modest cortisol excess</span></p><p class="headingAnchor" id="H632468868"><span class="h4">Unilateral adrenalectomy</span><span class="headingEndMark"> — </span>In patients with moderately increased cortisol production (the majority of PBMAH patients with Cushing's syndrome have less than threefold increase in UFC levels) but with clinical evidence of cortisol excess, we suggest unilateral adrenalectomy as it can restore UFC levels to normal [<a href="#rid3">3,102-105</a>]. However, as the cell mass subsequently increases in the contralateral adrenal, medical therapy with steroidogenesis inhibitors or a second adrenalectomy may become necessary [<a href="#rid98">98,102-104,106</a>].</p><p>In a review of 117 PBMAH cases from 23 publications treated with unilateral adrenalectomy, initial remission was achieved in 109 patients (93 percent). A total of 18 patients (15 percent) experienced a recurrence of hypercortisolism, and 16 patients (14 percent) required a completion contralateral adrenalectomy within a median time of 72 months. Transient hypocortisolism occurred in 32 percent and require careful monitoring and replacement with glucocorticoids [<a href="#rid3">3</a>].</p><p>In 15 patients with PBMAH treated by unilateral adrenalectomy, resection of the larger gland led to remission of hypercortisolism after three months in all 15 patients and a low risk of recurrence. In a second study of 25 PBMAH cases undergoing unilateral adrenalectomy, biochemical remission was initially achieved in 21 (84 percent) [<a href="#rid106">106</a>]. After a median of 50 months of follow-up, only eight patients (32 percent) were still biochemically controlled. Adrenalectomy of the contralateral side had to be performed in three (12 percent).</p><p>We do not suggest adrenal venous sampling to select which adrenal to remove, as standardization for data interpretation are lacking. In the largest study of 10 patients, an adrenal/peripheral vein ratio of ≥6.5 was considered consistent with a cortisol hypersecretion, and a cortisol lateralization ratio of ≤2.0 was in favor of bilateral source of cortisol [<a href="#rid107">107</a>]. The largest adrenal gland on computed tomography (CT) scan is selected for unilateral adrenalectomy [<a href="#rid3">3</a>].</p><p>Some experts have proposed alternative conservative surgical procedures in PBMAH patients with unilateral adrenalectomy on one side and subtotal contralateral adrenal resection [<a href="#rid108">108,109</a>]. In 17 patients, including 10 patients with modest cortisol excess, 95 percent achieved complete hypercortisolism control postoperatively, while 71 percent experienced recovery of their hypothalamic-pituitary-adrenal (HPA) axis at a median follow-up of 41 months. Only one patient developed relapse of hypercortisolism after 30 months requiring a completion surgery [<a href="#rid109">109</a>]. However, as many patients had only modest cortisol excess, the risk-benefit ratio of performing a bilateral procedure over unilateral adrenalectomy alone is not clear. It may be further evaluated prospectively in more severe cases rather than bilateral adrenalectomy [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H1721628700"><span class="h3">Minimal cortisol excess</span></p><p class="headingAnchor" id="H1559180438"><span class="h4">Monitoring without surgery</span><span class="headingEndMark"> — </span>In patients with very mild cortisol excess (normal UFC, normal corticotropin [ACTH], cortisol suppression following 1 mg overnight <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> &lt;5 mcg/dL) who are being monitored without adrenal surgery, clinical evaluation and biochemical assessment (1 mg overnight dexamethasone test, UFC, basal ACTH, fasting glucose) every 6 to 12 months and yearly CT scan are sufficient as PBMAH is a benign process that has not been shown to become malignant.</p><p>We suggest unilateral adrenalectomy if there is disease progression with increased UFC, complete suppression of ACTH, and clinical effects of hypercortisolism such as osteoporosis, diabetes, hypertension, or neuropsychological manifestations (see <a class="local">'Unilateral adrenalectomy'</a> above). As studies in unilateral adrenal incidentaloma have reported progressive adverse cardiovascular outcomes in patients with plasma cortisol &gt;5.1 mcg/dL (140 nmol/L) after a 1 mg <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> test [<a href="#rid110">110,111</a>], we are more commonly referring patients to unilateral adrenalectomy when signs of cortisol excess develop.</p><p class="headingAnchor" id="H677931018"><span class="h2">Patients with PBMAH and aberrant receptors</span></p><p class="headingAnchor" id="H21362891"><span class="h3">Pharmacologic therapy</span><span class="headingEndMark"> — </span>In some patients in whom aberrant hormone receptors have been identified, specific pharmacologic therapies blocking the aberrant receptors can be effective as alternatives to adrenalectomy. Despite normalization of cortisol secretion with specific aberrant receptor-targeted therapy, no tumor regression has been observed; this may be secondary to incomplete receptor blockade or to the possibility that proliferation is regulated by armadillo repeat-containing 5 gene (<em>ARMC5)</em> mutations or other secondary genetic events [<a href="#rid5">5,44,61,112</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>We suggest beta blocker therapy for PBMAH patients with Cushing's syndrome and aberrant beta-adrenergic receptors. In catecholamine-dependent Cushing's syndrome and PBMAH, beta-adrenergic receptor antagonists (<a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>) are effective in the long-term control of hypercortisolism [<a href="#rid10">10,19,22</a>]. Propranolol can be started at 60 mg/day, increasing every two weeks up to 320 mg/day in two to three divided doses in order to achieve mid-normal levels of UFC. We suggest monitoring patients weekly initially for the first month (UFC, blood pressure, pulse), monthly for three months and every three months if stable afterwards.</p><p></p><p class="bulletIndent1">In patients who experience side effects such as nightmares or who have compliance problems with split doses of <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, we have used <a class="drug drug_general" data-topicid="9672" href="/d/drug information/9672.html" rel="external">nadolol</a>, another nonselective antagonist that is administered as a single daily dose (40 to 320 mg).</p><p></p><p class="bulletIndent1">Symptomatic bradycardia without reaching normalized UFC may limit the use of beta-adrenergic receptor antagonists so that bilateral adrenalectomy is required. If beta-adrenergic receptor antagonists do not normalize UFC, we suggest adrenalectomy. (See <a class="local">'Bilateral adrenalectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest gonadotropin-releasing hormone (GnRH) agonist therapy for patients with luteinizing hormone (LH) or human chorionic gonadotropin (hCG) receptors. In LH/hCG-dependent PBMAH and Cushing's syndrome, suppression of endogenous LH levels with long-acting <a class="drug drug_general" data-topicid="9549" href="/d/drug information/9549.html" rel="external">leuprolide</a> acetate controlled steroid secretion and avoided bilateral adrenalectomy [<a href="#rid23">23,25</a>]. We typically use a monthly dose of depot leuprolide acetate (3.75 mg intramuscular).</p><p></p><p class="bulletIndent1">Levels of 24-hour UFC, morning plasma cortisol, and LH levels are monitored two and four weeks after the first injection. Treatment is continued if UFC normalizes or improves at least by 50 percent within the first three months based upon two UFC samples each month. If UFC levels are not normalized within three months, unilateral or bilateral adrenalectomy is recommended, depending on levels of cortisol excess as described previously.</p><p></p><p class="bulletIndent1">For patients who are well controlled on GnRH agonist therapy, we suggest follow-up every three to four months for the first year (with UFC, morning plasma cortisol, and serum LH). Of note, we have followed patients every six months thereafter; some have remained controlled for more than 10 years. In premenopausal women or males, we suggest adding gonadal steroids to the GnRH agonist to avoid the consequences of hypogonadism (estrogen-progestin therapy in women and <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> in men). We also suggest monitoring bone mineral density. (See  <a class="medical medical_review" href="/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists", section on 'GnRH with add-back therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with gastric inhibitory polypeptide (GIP)-dependent Cushing's syndrome, we suggest surgical adrenalectomy rather than pharmacologic therapy (see <a class="local">'Aberrant hormone receptors'</a> above). Pharmacologic blockade of postprandial release of GIP with <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> or <a class="drug drug_general" data-topicid="87457" href="/d/drug information/87457.html" rel="external">pasireotide</a> leads to clinical and biochemical improvement of Cushing's syndrome, but the beneficial effect does not persist in the long term, probably because of eventual desensitization of somatostatin receptors in GIP-secreting duodenal K cells [<a href="#rid35">35,36,40</a>]. Thus, we suggest surgical adrenalectomy in these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When specific receptor antagonists for ACTH, <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>, serotonin, GIP, or other aberrant receptors become available, a broader range of pharmacologic therapies could become useful [<a href="#rid48">48,49</a>]. Until these become available, surgical adrenalectomy is recommended.</p><p></p><p class="headingAnchor" id="H3974919429"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112709.html" rel="external">"Society guideline links: Diagnosis and treatment of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Primary bilateral macronodular adrenal hyperplasia (PBMAH) has been described by various terms, including corticotropin (ACTH)-independent macronodular adrenal hyperplasia (AIMAH), primary macronodular adrenal hyperplasia (PMAH), massive macronodular adrenocortical disease (MMAD), autonomous macronodular adrenal hyperplasia (AMAH), ACTH-independent massive bilateral adrenal disease (AIMBAD), and "giant" or "huge" macronodular adrenal disease. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PBMAH is more frequently familial than previously believed (autosomal dominant transmission), and approximately 25 percent of apparent sporadic cases carry a germline mutation of armadillo repeat-containing 5 gene (<em>ARMC5</em>). The disease appears heterogeneous as several other genetic abnormalities can be rarely associated. (See <a class="local">'Genetic causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PBMAH results in hypercortisolism through a number of mechanisms that are described above (see <a class="local">'Pathogenesis'</a> above). In the majority of patients with PBMAH, cortisol appears to be regulated by a number of aberrant G-protein-coupled receptors (GPCRs) and by locally produced ACTH. Aberrant receptors include <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>, serotonin 5-hydroxytryptamine 4 (5-HT4), gastric inhibitory polypeptide (GIP), beta-adrenergic, luteinizing hormone (LH)/human chorionic gonadotropin (hCG), and others. (See <a class="local">'Aberrant hormone receptors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical presentation and biochemical findings of Cushing's syndrome in PBMAH are similar to those seen in other types of ACTH-independent Cushing's syndrome. However, patients with PBMAH typically have a later age of onset (fifth and sixth decades), and patients with GIP-dependent Cushing's syndrome have a unique pattern of cortisol hypersecretion ("food dependent") (<a class="graphic graphic_table graphicRef50582" href="/d/graphic/50582.html" rel="external">table 1</a>). (See <a class="local">'Aberrant hormone receptors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of PBMAH is made in patients with overt Cushing's syndrome and suppressed ACTH and dehydroepiandrosterone sulfate (DHEAS) levels with bilaterally enlarged nodular adrenals. The diagnosis is also made in patients with incidentally found bilateral diffusely enlarged adrenals or with multinodular adrenals and mild hypercortisolism in whom a subnormal suppression of cortisol is found (&gt;1.8 mcg/dL or &gt;50 nmol/L) following 1 mg overnight <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with PBMAH can be distinguished from those with chronic ACTH-dependent Cushing's syndrome (Cushing's disease or ectopic ACTH) with bilateral nodular adrenal hyperplasia who have elevated ACTH levels. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with PBMAH and clinical or mild Cushing's syndrome should undergo testing for aberrant receptors as this may change the therapeutic strategy. (See <a class="local">'Aberrant hormone receptors'</a> above and <a class="local">'Screening for aberrant receptors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition, we recommend screening of first-degree relatives of index cases without known genetic mutation using 1 mg overnight <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test for the presence of familial PBMAH. Genetic screening for <em>ARMC5</em> (or eventually other genes responsible for PBMAH) has become available to screen first-degree relatives of index cases. (See <a class="local">'Screening family members'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with PBMAH in whom aberrant hormone receptors are not present or for which no specific pharmacologic blockade is available or effective:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We perform bilateral adrenalectomy for very severe Cushing's syndrome with urinary free cortisol (UFC) &gt;3 times the upper limit of normal and equally enlarged adrenals. (See  <a class="medical medical_review" href="/d/html/16322.html" rel="external">"Persistent or recurrent Cushing disease: Surgical adrenalectomy"</a>.)</p><p></p><p class="bulletIndent2">In similar patients but with very asymmetric adrenal size, unilateral resection of the largest adrenal can be performed. (See <a class="local">'Unilateral adrenalectomy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with moderately increased cortisol production (less than threefold increase in UFC levels) and clinical evidence of cortisol excess, we suggest unilateral adrenalectomy as it can restore UFC levels to normal (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'Unilateral adrenalectomy'</a> above). Such patients can present transient secondary adrenal insufficiency and require glucocorticoid replacement postoperatively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with PBMAH and normal levels of urinary cortisol, the decision between observation and surgery should be based on biochemical (suppressed ACTH, elevated late-night salivary cortisol, and cortisol &gt;5 mg/dL following 1 mg <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> overnight test) and clinical evidence of cortisol excess (hypertension, diabetes, osteoporosis, or neuropsychological manifestations). (See <a class="local">'Minimal cortisol excess'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with PBMAH and overt Cushing's syndrome regulated by aberrant receptors (see <a class="local">'Patients with PBMAH and aberrant receptors'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest treatment with beta-blockers for patients with PBMAH and aberrant beta-adrenergic receptors (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Pharmacologic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest treatment with gonadotropin-releasing hormone (GnRH) agonists (and sex steroid replacement) for patients with PBMAH and LH/hCG receptors (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Pharmacologic therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H103536535"><span class="h1">DISCLOSURE</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23:245.</a></li><li><a class="nounderline abstract_t">Bourdeau I, El Ghorayeb N, Gagnon N, Lacroix A. MANAGEMENT OF ENDOCRINE DISEASE: Differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas. Eur J Endocrinol 2018; 179:R57.</a></li><li><a class="nounderline abstract_t">Meloche-Dumas L, Mercier F, Lacroix A. Role of unilateral adrenalectomy in bilateral adrenal hyperplasias with Cushing's syndrome. Best Pract Res Clin Endocrinol Metab 2021; 35:101486.</a></li><li><a class="nounderline abstract_t">Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001; 22:75.</a></li><li><a class="nounderline abstract_t">Lacroix A, Baldacchino V, Bourdeau I, et al. Cushing's syndrome variants secondary to aberrant hormone receptors. Trends Endocrinol Metab 2004; 15:375.</a></li><li><a class="nounderline abstract_t">Libé R, Coste J, Guignat L, et al. Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome. Eur J Endocrinol 2010; 163:129.</a></li><li><a class="nounderline abstract_t">Hsiao HP, Kirschner LS, Bourdeau I, et al. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab 2009; 94:2930.</a></li><li><a class="nounderline abstract_t">Mircescu H, Jilwan J, N'Diaye N, et al. Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing's syndrome? J Clin Endocrinol Metab 2000; 85:3531.</a></li><li><a class="nounderline abstract_t">Hofland J, Hofland LJ, van Koetsveld PM, et al. ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase. Orphanet J Rare Dis 2013; 8:142.</a></li><li><a class="nounderline abstract_t">El Ghorayeb N, Bourdeau I, Lacroix A. Multiple aberrant hormone receptors in Cushing's syndrome. Eur J Endocrinol 2015; 173:M45.</a></li><li><a class="nounderline abstract_t">Bourdeau I, D'Amour P, Hamet P, et al. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome. J Clin Endocrinol Metab 2001; 86:5534.</a></li><li><a class="nounderline abstract_t">Bertherat J, Contesse V, Louiset E, et al. In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome: identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism. J Clin Endocrinol Metab 2005; 90:1302.</a></li><li><a class="nounderline abstract_t">Horiba N, Suda T, Aiba M, et al. Lysine vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 1995; 80:2336.</a></li><li><a class="nounderline abstract_t">Lacroix A, Tremblay J, Touyz RM, et al. Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. J Clin Endocrinol Metab 1997; 82:2414.</a></li><li><a class="nounderline abstract_t">Mune T, Murase H, Yamakita N, et al. Eutopic overexpression of vasopressin v1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2002; 87:5706.</a></li><li><a class="nounderline abstract_t">Miyamura N, Taguchi T, Murata Y, et al. Inherited adrenocorticotropin-independent macronodular adrenal hyperplasia with abnormal cortisol secretion by vasopressin and catecholamines: detection of the aberrant hormone receptors on adrenal gland. Endocrine 2002; 19:319.</a></li><li><a class="nounderline abstract_t">Lee S, Hwang R, Lee J, et al. Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH-independent macronodular adrenal hyperplasia. Clin Endocrinol (Oxf) 2005; 63:625.</a></li><li><a class="nounderline abstract_t">Vezzosi D, Cartier D, Régnier C, et al. Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. Eur J Endocrinol 2007; 156:21.</a></li><li><a class="nounderline abstract_t">Lacroix A, Tremblay J, Rousseau G, et al. Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing's syndrome. N Engl J Med 1997; 337:1429.</a></li><li><a class="nounderline abstract_t">Bourdeau I, Oble S, Magne F, et al. ARMC5 mutations in a large French-Canadian family with cortisol-secreting β-adrenergic/vasopressin responsive bilateral macronodular adrenal hyperplasia. Eur J Endocrinol 2016; 174:85.</a></li><li><a class="nounderline abstract_t">Miyamura N, Tsutsumi A, Senokuchi H, et al. A case of ACTH-independent macronodular adrenal hyperplasia: simultaneous expression of several aberrant hormone receptors in the adrenal gland. Endocr J 2003; 50:333.</a></li><li><a class="nounderline abstract_t">Mazzuco TL, Thomas M, Martinie M, et al. Cellular and molecular abnormalities of a macronodular adrenal hyperplasia causing beta-blocker-sensitive Cushing's syndrome. Arq Bras Endocrinol Metabol 2007; 51:1452.</a></li><li><a class="nounderline abstract_t">Lacroix A, Hamet P, Boutin JM. Leuprolide acetate therapy in luteinizing hormone--dependent Cushing's syndrome. N Engl J Med 1999; 341:1577.</a></li><li><a class="nounderline abstract_t">Plöckinger U, Chrusciel M, Doroszko M, et al. Functional Implications of LH/hCG Receptors in Pregnancy-Induced Cushing Syndrome. J Endocr Soc 2017; 1:57.</a></li><li><a class="nounderline abstract_t">Goodarzi MO, Dawson DW, Li X, et al. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab 2003; 88:73.</a></li><li><a class="nounderline abstract_t">Hannah-Shmouni F, Moraitis AG, Romero VV, et al. Successful Treatment of Estrogen Excess in Primary Bilateral Macronodular Adrenocortical Hyperplasia with Leuprolide Acetate. Horm Metab Res 2018; 50:124.</a></li><li><a class="nounderline abstract_t">Feelders RA, Lamberts SW, Hofland LJ, et al. Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro. J Clin Endocrinol Metab 2003; 88:230.</a></li><li><a class="nounderline abstract_t">Cartier D, Lihrmann I, Parmentier F, et al. Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. J Clin Endocrinol Metab 2003; 88:248.</a></li><li><a class="nounderline abstract_t">Mannelli M, Ferruzzi P, Luciani P, et al. Cushing's syndrome in a patient with bilateral macronodular adrenal hyperplasia responding to cisapride: an in vivo and in vitro study. J Clin Endocrinol Metab 2003; 88:4616.</a></li><li><a class="nounderline abstract_t">Louiset E, Contesse V, Groussin L, et al. Expression of serotonin7 receptor and coupling of ectopic receptors to protein kinase A and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome. J Clin Endocrinol Metab 2006; 91:4578.</a></li><li><a class="nounderline abstract_t">Shenker A, Weinstein LS, Moran A, et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993; 123:509.</a></li><li><a class="nounderline abstract_t">Burgess JR, Harle RA, Tucker P, et al. Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Arch Surg 1996; 131:699.</a></li><li><a class="nounderline abstract_t">Swords FM, Baig A, Malchoff DM, et al. Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. Mol Endocrinol 2002; 16:2746.</a></li><li><a class="nounderline abstract_t">Lacroix A, Bolté E, Tremblay J, et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of Cushing's syndrome. N Engl J Med 1992; 327:974.</a></li><li><a class="nounderline abstract_t">Reznik Y, Allali-Zerah V, Chayvialle JA, et al. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 1992; 327:981.</a></li><li><a class="nounderline abstract_t">de Herder WW, Hofland LJ, Usdin TB, et al. Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. J Clin Endocrinol Metab 1996; 81:3168.</a></li><li><a class="nounderline abstract_t">Groussin L, Perlemoine K, Contesse V, et al. The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia, but rare in unilateral tumors. J Clin Endocrinol Metab 2002; 87:1980.</a></li><li><a class="nounderline abstract_t">N'Diaye N, Tremblay J, Hamet P, et al. Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushing's syndrome. J Clin Endocrinol Metab 1998; 83:2781.</a></li><li><a class="nounderline abstract_t">N'Diaye N, Hamet P, Tremblay J, et al. Asynchronous development of bilateral nodular adrenal hyperplasia in gastric inhibitory polypeptide-dependent cushing's syndrome. J Clin Endocrinol Metab 1999; 84:2616.</a></li><li><a class="nounderline abstract_t">Preumont V, Mermejo LM, Damoiseaux P, et al. Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome. Horm Metab Res 2011; 43:287.</a></li><li><a class="nounderline abstract_t">Larose S, Bondaz L, Mermejo LM, et al. Coexistence of Myelolipoma and Primary Bilateral Macronodular Adrenal Hyperplasia With GIP-Dependent Cushing's Syndrome. Front Endocrinol (Lausanne) 2019; 10:618.</a></li><li><a class="nounderline abstract_t">Lampron A, Bourdeau I, Oble S, et al. Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. J Clin Endocrinol Metab 2009; 94:750.</a></li><li><a class="nounderline abstract_t">Lecoq AL, Stratakis CA, Viengchareun S, et al. Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushing's syndrome. JCI Insight 2017; 2.</a></li><li><a class="nounderline abstract_t">Lampron A, Bourdeau I, Hamet P, et al. Whole genome expression profiling of glucose-dependent insulinotropic peptide (GIP)- and adrenocorticotropin-dependent adrenal hyperplasias reveals novel targets for the study of GIP-dependent Cushing's syndrome. J Clin Endocrinol Metab 2006; 91:3611.</a></li><li><a class="nounderline abstract_t">Albiger NM, Occhi G, Mariniello B, et al. Food-dependent Cushing's syndrome: from molecular characterization to therapeutical results. Eur J Endocrinol 2007; 157:771.</a></li><li><a class="nounderline abstract_t">Nakamura Y, Son Y, Kohno Y, et al. Case of adrenocorticotropic hormone-independent macronodular adrenal hyperplasia with possible adrenal hypersensitivity to angiotensin II. Endocrine 2001; 15:57.</a></li><li><a class="nounderline abstract_t">Assie G, Louiset E, Sturm N, et al. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome. J Clin Endocrinol Metab 2010; 95:E253.</a></li><li><a class="nounderline abstract_t">Lacroix A. Heredity and cortisol regulation in bilateral macronodular adrenal hyperplasia. N Engl J Med 2013; 369:2147.</a></li><li><a class="nounderline abstract_t">Louiset E, Duparc C, Young J, et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med 2013; 369:2115.</a></li><li><a class="nounderline abstract_t">Cavalcante IP, Nishi M, Zerbini MCN, et al. The role of ARMC5 in human cell cultures from nodules of primary macronodular adrenocortical hyperplasia (PMAH). Mol Cell Endocrinol 2018; 460:36.</a></li><li><a class="nounderline abstract_t">KIRSCHNER MA, POWELL RD Jr, LIPSETT MB. CUSHING'S SYNDROME: NODULAR CORTICAL HYPERPLASIA OF ADRENAL GLANDS WITH CLINICAL AND PATHOLOGICAL FEATURES SUGGESTING ADRENOCORTICAL TUMOR. J Clin Endocrinol Metab 1964; 24:947.</a></li><li><a class="nounderline abstract_t">Cheitlin RA, Westphal M, Cabrera CM, et al. Cushing's syndrome due to bilateral adrenal macronodular hyperplasia with undetectable ACTH: cell culture of adenoma cells on extracellular matrix. Horm Res 1988; 29:162.</a></li><li><a class="nounderline abstract_t">Malchoff CD, Rosa J, DeBold CR, et al. Adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia: an unusual cause of Cushing's syndrome. J Clin Endocrinol Metab 1989; 68:855.</a></li><li><a class="nounderline abstract_t">Swain JM, Grant CS, Schlinkert RT, et al. Corticotropin-independent macronodular adrenal hyperplasia: a clinicopathologic correlation. Arch Surg 1998; 133:541.</a></li><li><a class="nounderline abstract_t">Findlay JC, Sheeler LR, Engeland WC, Aron DC. Familial adrenocorticotropin-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 1993; 76:189.</a></li><li><a class="nounderline abstract_t">Minami S, Sugihara H, Sato J, et al. ACTH independent Cushing's syndrome occurring in siblings. Clin Endocrinol (Oxf) 1996; 44:483.</a></li><li><a class="nounderline abstract_t">Nies C, Bartsch DK, Ehlenz K, et al. Familial ACTH-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia clinically affecting only female family members. Exp Clin Endocrinol Diabetes 2002; 110:277.</a></li><li><a class="nounderline abstract_t">Imöhl M, Köditz R, Stachon A, et al. [Catecholamine-dependent hereditary Cushing's syndrome - follow-up after unilateral adrenalectomy]. Med Klin (Munich) 2002; 97:747.</a></li><li><a class="nounderline abstract_t">Koyano H, Someya T, Osawa Y. ACTH-independent macronodular adrenocortical hyperplasia (AIMAH) in two brothers and a sister. Folia Endocrinol 1996; 72:762.</a></li><li><a class="nounderline abstract_t">Watson TD, Patel SJ, Nardi PM. Case 121: familial adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing syndrome. Radiology 2007; 244:923.</a></li><li><a class="nounderline abstract_t">Assié G, Libé R, Espiard S, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med 2013; 369:2105.</a></li><li><a class="nounderline abstract_t">Faucz FR, Zilbermint M, Lodish MB, et al. Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. J Clin Endocrinol Metab 2014; 99:E1113.</a></li><li><a class="nounderline abstract_t">Alencar GA, Lerario AM, Nishi MY, et al. ARMC5 mutations are a frequent cause of primary macronodular adrenal Hyperplasia. J Clin Endocrinol Metab 2014; 99:E1501.</a></li><li><a class="nounderline abstract_t">Espiard S, Drougat L, Libé R, et al. ARMC5 Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional Consequences. J Clin Endocrinol Metab 2015; 100:E926.</a></li><li><a class="nounderline abstract_t">Albiger NM, Regazzo D, Rubin B, et al. A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype. Endocrine 2017; 55:959.</a></li><li><a class="nounderline abstract_t">Correa R, Zilbermint M, Berthon A, et al. The ARMC5 gene shows extensive genetic variance in primary macronodular adrenocortical hyperplasia. Eur J Endocrinol 2015; 173:435.</a></li><li><a class="nounderline abstract_t">Jin P, Janjua MU, Zhang Q, et al. Extensive ARMC5 genetic variance in primary bilateral macronodular adrenal hyperplasia that started with exophthalmos: a case report. J Med Case Rep 2018; 12:13.</a></li><li><a class="nounderline abstract_t">Gagliardi L, Schreiber AW, Hahn CN, et al. ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2014; 99:E1784.</a></li><li><a class="nounderline abstract_t">Elbelt U, Trovato A, Kloth M, et al. Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma. J Clin Endocrinol Metab 2015; 100:E119.</a></li><li><a class="nounderline abstract_t">Yu L, Zhang J, Guo X, et al. ARMC5 mutations in familial and sporadic primary bilateral macronodular adrenal hyperplasia. PLoS One 2018; 13:e0191602.</a></li><li><a class="nounderline abstract_t">Suzuki S, Tatsuno I, Oohara E, et al. GERMLINE DELETION OF ARMC5 IN FAMILIAL PRIMARY MACRONODULAR ADRENAL HYPERPLASIA. Endocr Pract 2015; 21:1152.</a></li><li><a class="nounderline abstract_t">Hu Y, Lao L, Mao J, et al. Armc5 deletion causes developmental defects and compromises T-cell immune responses. Nat Commun 2017; 8:13834.</a></li><li><a class="nounderline abstract_t">Berthon A, Faucz FR, Espiard S, et al. Age-dependent effects of Armc5 haploinsufficiency on adrenocortical function. Hum Mol Genet 2017; 26:3495.</a></li><li><a class="nounderline abstract_t">Swords FM, Aylwin S, Perry L, et al. The aberrant expression of the gastric inhibitory polypeptide (GIP) receptor in adrenal hyperplasia: does chronic adrenocorticotropin exposure stimulate up-regulation of GIP receptors in Cushing's disease? J Clin Endocrinol Metab 2005; 90:3009.</a></li><li><a class="nounderline abstract_t">Mariani BMP, Nishi MY, Wanichi IQ, et al. Allelic Variants of ARMC5 in Patients With Adrenal Incidentalomas and in Patients With Cushing's Syndrome Associated With Bilateral Adrenal Nodules. Front Endocrinol (Lausanne) 2020; 11:36.</a></li><li><a class="nounderline abstract_t">Ringel MD, Schwindinger WF, Levine MA. Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 1996; 75:171.</a></li><li><a class="nounderline abstract_t">Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325:1688.</a></li><li><a class="nounderline abstract_t">Boston BA, Mandel S, LaFranchi S, Bliziotes M. Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia. J Clin Endocrinol Metab 1994; 79:890.</a></li><li><a class="nounderline abstract_t">Fragoso MC, Domenice S, Latronico AC, et al. Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J Clin Endocrinol Metab 2003; 88:2147.</a></li><li><a class="nounderline abstract_t">Gatta-Cherifi B, Chabre O, Murat A, et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database. Eur J Endocrinol 2012; 166:269.</a></li><li><a class="nounderline abstract_t">Kartheuser A, Walon C, West S, et al. Familial adenomatous polyposis associated with multiple adrenal adenomas in a patient with a rare 3' APC mutation. J Med Genet 1999; 36:65.</a></li><li><a class="nounderline abstract_t">Matyakhina L, Freedman RJ, Bourdeau I, et al. Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical cushing syndrome: a clinical and molecular genetic investigation. J Clin Endocrinol Metab 2005; 90:3773.</a></li><li><a class="nounderline abstract_t">Libé R, Fratticci A, Coste J, et al. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res 2008; 14:4016.</a></li><li><a class="nounderline abstract_t">Skogseid B, Larsson C, Lindgren PG, et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1992; 75:76.</a></li><li><a class="nounderline abstract_t">Oheda T, Noguchi Y, Morio H, et al. Study on steroidogenic activity of ACTH-independent macronodular adrenocortical hyperplasia which occurred in brothers in a cancer family. Folia Endocrinologica 1995; 71:416.</a></li><li><a class="nounderline abstract_t">De Venanzi A, Alencar GA, Bourdeau I, et al. Primary bilateral macronodular adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes 2014; 21:177.</a></li><li><a class="nounderline abstract_t">Fragoso MC, Alencar GA, Lerario AM, et al. Genetics of primary macronodular adrenal hyperplasia. J Endocrinol 2015; 224:R31.</a></li><li><a class="nounderline abstract_t">Drougat L, Espiard S, Bertherat J. Genetics of primary bilateral macronodular adrenal hyperplasia: a model for early diagnosis of Cushing's syndrome? Eur J Endocrinol 2015; 173:M121.</a></li><li><a class="nounderline abstract_t">Wada S, Kitahama S, Togashi A, et al. Preclinical Cushing's syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia with excessive secretion of 18-hydroxydeoxycorticosterone and corticosterone. Intern Med 2002; 41:304.</a></li><li><a class="nounderline abstract_t">Tokumoto M, Onoda N, Tauchi Y, et al. A case of Adrenocoricotrophic hormone -independent bilateral adrenocortical macronodular hyperplasia concomitant with primary aldosteronism. BMC Surg 2017; 17:97.</a></li><li><a class="nounderline abstract_t">Ghayee HK, Rege J, Watumull LM, et al. Clinical, biochemical, and molecular characterization of macronodular adrenocortical hyperplasia of the zona reticularis: a new syndrome. J Clin Endocrinol Metab 2011; 96:E243.</a></li><li><a class="nounderline abstract_t">Doppman JL, Chrousos GP, Papanicolaou DA, et al. Adrenocorticotropin-independent macronodular adrenal hyperplasia: an uncommon cause of primary adrenal hypercortisolism. Radiology 2000; 216:797.</a></li><li><a class="nounderline abstract_t">Alencar GA, Fragoso MC, Yamaga LY, et al. (18)F-FDG-PET/CT imaging of ACTH-independent macronodular adrenocortical hyperplasia (AIMAH) demonstrating increased (18)F-FDG uptake. J Clin Endocrinol Metab 2011; 96:3300.</a></li><li><a class="nounderline abstract_t">Cavalcante IP, Zerbini MC, Alencar GA, et al. High 18F-FDG uptake in PMAH correlated with normal expression of Glut1, HK1, HK2, and HK3. Acta Radiol 2016; 57:370.</a></li><li><a class="nounderline abstract_t">Aron DC, Findling JW, Fitzgerald PA, et al. Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing's syndrome. Report of two cases and review of the literature. Am J Med 1981; 71:302.</a></li><li><a class="nounderline abstract_t">Smals AG, Pieters GF, van Haelst UJ, Kloppenborg PW. Macronodular adrenocortical hyperplasia in long-standing Cushing's disease. J Clin Endocrinol Metab 1984; 58:25.</a></li><li><a class="nounderline abstract_t">Vassiliadi DA, Ntali G, Stratigou T, et al. Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas. Endocrine 2011; 40:437.</a></li><li><a class="nounderline abstract_t">Debillon E, Velayoudom-Cephise FL, Salenave S, et al. Unilateral Adrenalectomy as a First-Line Treatment of Cushing's Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia. J Clin Endocrinol Metab 2015; 100:4417.</a></li><li><a class="nounderline abstract_t">Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100:2807.</a></li><li><a class="nounderline abstract_t">Malchoff CD, MacGillvray D, Malchoff DM. Adrenocortical hormone-independent adrenal hyperplasia. Endocrinologist 1996; 6:79.</a></li><li><a class="nounderline abstract_t">Feelders RA, Newell-Price J, Pivonello R, et al. Advances in the medical treatment of Cushing's syndrome. Lancet Diabetes Endocrinol 2019; 7:300.</a></li><li><a class="nounderline abstract_t">Boronat M, Lucas T, Barceló B, et al. Cushing's syndrome due to autonomous macronodular adrenal hyperplasia: long-term follow-up after unilateral adrenalectomy. Postgrad Med J 1996; 72:614.</a></li><li><a class="nounderline abstract_t">Lamas C, Alfaro JJ, Lucas T, et al. Is unilateral adrenalectomy an alternative treatment for ACTH-independent macronodular adrenal hyperplasia?: Long-term follow-up of four cases. Eur J Endocrinol 2002; 146:237.</a></li><li><a class="nounderline abstract_t">Iacobone M, Albiger N, Scaroni C, et al. The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal hyperplasia (AIMAH). World J Surg 2008; 32:882.</a></li><li><a class="nounderline abstract_t">Xu Y, Rui W, Qi Y, et al. The role of unilateral adrenalectomy in corticotropin-independent bilateral adrenocortical hyperplasias. World J Surg 2013; 37:1626.</a></li><li><a class="nounderline abstract_t">Osswald A, Quinkler M, Di Dalmazi G, et al. Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. J Clin Endocrinol Metab 2019; 104:2985.</a></li><li><a class="nounderline abstract_t">Young WF Jr, du Plessis H, Thompson GB, et al. The clinical conundrum of corticotropin-independent autonomous cortisol secretion in patients with bilateral adrenal masses. World J Surg 2008; 32:856.</a></li><li><a class="nounderline abstract_t">Lowery AJ, Seeliger B, Alesina PF, Walz MK. Posterior retroperitoneoscopic adrenal surgery for clinical and subclinical Cushing's syndrome in patients with bilateral adrenal disease. Langenbecks Arch Surg 2017; 402:775.</a></li><li><a class="nounderline abstract_t">Yoshiaki Tanno F, Srougi V, Almeida MQ, et al. A New Insight into the Surgical Treatment of Primary Macronodular Adrenal Hyperplasia. J Endocr Soc 2020; 4:bvaa083.</a></li><li><a class="nounderline abstract_t">Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2014; 2:396.</a></li><li><a class="nounderline abstract_t">Debono M, Bradburn M, Bull M, et al. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 2014; 99:4462.</a></li><li><a class="nounderline abstract_t">Almeida MQ, Harran M, Bimpaki EI, et al. Integrated genomic analysis of nodular tissue in macronodular adrenocortical hyperplasia: progression of tumorigenesis in a disorder associated with multiple benign lesions. J Clin Endocrinol Metab 2011; 96:E728.</a></li></ol></div><div id="topicVersionRevision">Topic 148 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19500767" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ACTH-independent macronodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29748231" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : MANAGEMENT OF ENDOCRINE DISEASE: Differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33637447" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Role of unilateral adrenalectomy in bilateral adrenal hyperplasias with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11159817" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15380809" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cushing's syndrome variants secondary to aberrant hormone receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20378721" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19509103" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11061496" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing's syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24034279" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25971648" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Multiple aberrant hormone receptors in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701732" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585558" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome: identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629226" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lysine vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253310" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12466375" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Eutopic overexpression of vasopressin v1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12624433" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Inherited adrenocorticotropin-independent macronodular adrenal hyperplasia with abnormal cortisol secretion by vasopressin and catecholamines: detection of the aberrant hormone receptors on adrenal gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16343095" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH-independent macronodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218722" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9358140" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26604299" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : ARMC5 mutations in a large French-Canadian family with cortisol-secretingβ-adrenergic/vasopressin responsive bilateral macronodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940463" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A case of ACTH-independent macronodular adrenal hyperplasia: simultaneous expression of several aberrant hormone receptors in the adrenal gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18209887" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cellular and molecular abnormalities of a macronodular adrenal hyperplasia causing beta-blocker-sensitive Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10564687" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Leuprolide acetate therapy in luteinizing hormone--dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29264446" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Functional Implications of LH/hCG Receptors in Pregnancy-Induced Cushing Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519832" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29183089" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Successful Treatment of Estrogen Excess in Primary Bilateral Macronodular Adrenocortical Hyperplasia with Leuprolide Acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519858" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519861" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557431" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cushing's syndrome in a patient with bilateral macronodular adrenal hyperplasia responding to cisapride: an in vivo and in vitro study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16954157" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Expression of serotonin7 receptor and coupling of ectopic receptors to protein kinase A and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8410501" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8678766" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12456795" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1325608" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1325609" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8784063" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11994328" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia, but rare in unilateral tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709947" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443649" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Asynchronous development of bilateral nodular adrenal hyperplasia in gastric inhibitory polypeptide-dependent cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21264796" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31572300" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Coexistence of Myelolipoma and Primary Bilateral Macronodular Adrenal Hyperplasia With GIP-Dependent Cushing's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19066304" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28931750" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16772347" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Whole genome expression profiling of glucose-dependent insulinotropic peptide (GIP)- and adrenocorticotropin-dependent adrenal hyperplasias reveals novel targets for the study of GIP-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057385" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Food-dependent Cushing's syndrome: from molecular characterization to therapeutical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11572327" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Case of adrenocorticotropic hormone-independent macronodular adrenal hyperplasia with possible adrenal hypersensitivity to angiotensin II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660048" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24283229" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Heredity and cortisol regulation in bilateral macronodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24283225" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28676429" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The role of ARMC5 in human cell cultures from nodules of primary macronodular adrenocortical hyperplasia (PMAH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14228534" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : CUSHING'S SYNDROME: NODULAR CORTICAL HYPERPLASIA OF ADRENAL GLANDS WITH CLINICAL AND PATHOLOGICAL FEATURES SUGGESTING ADRENOCORTICAL TUMOR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2851520" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cushing's syndrome due to bilateral adrenal macronodular hyperplasia with undetectable ACTH: cell culture of adenoma cells on extracellular matrix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2537845" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia: an unusual cause of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9605918" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Corticotropin-independent macronodular adrenal hyperplasia: a clinicopathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8380604" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Familial adrenocorticotropin-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8706318" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : ACTH independent Cushing's syndrome occurring in siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373631" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Familial ACTH-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia clinically affecting only female family members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12564422" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : [Catecholamine-dependent hereditary Cushing's syndrome - follow-up after unilateral adrenalectomy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : ACTH-independent macronodular adrenocortical hyperplasia (AIMAH) in two brothers and a sister</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17709841" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Case 121: familial adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24283224" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24601692" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24708098" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : ARMC5 mutations are a frequent cause of primary macronodular adrenal Hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25853793" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : ARMC5 Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional Consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27094308" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26162405" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The ARMC5 gene shows extensive genetic variance in primary macronodular adrenocortical hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29343284" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Extensive ARMC5 genetic variance in primary bilateral macronodular adrenal hyperplasia that started with exophthalmos: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24905064" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25279498" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370219" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : ARMC5 mutations in familial and sporadic primary bilateral macronodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26214113" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : GERMLINE DELETION OF ARMC5 IN FAMILIAL PRIMARY MACRONODULAR ADRENAL HYPERPLASIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28169274" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Armc5 deletion causes developmental defects and compromises T-cell immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28911199" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Age-dependent effects of Armc5 haploinsufficiency on adrenocortical function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705925" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The aberrant expression of the gastric inhibitory polypeptide (GIP) receptor in adrenal hyperplasia: does chronic adrenocorticotropin exposure stimulate up-regulation of GIP receptors in Cushing's disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32117062" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Allelic Variants of ARMC5 in Patients With Adrenal Incidentalomas and in Patients With Cushing's Syndrome Associated With Bilateral Adrenal Nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8699958" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1944469" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8077378" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12727968" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22084155" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9950370" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Familial adenomatous polyposis associated with multiple adrenal adenomas in a patient with a rare 3' APC mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741255" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical cushing syndrome: a clinical and molecular genetic investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559625" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1352309" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Study on steroidogenic activity of ACTH-independent macronodular adrenocortical hyperplasia which occurred in brothers in a cancer family</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24739311" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Primary bilateral macronodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25472909" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Genetics of primary macronodular adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26264719" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Genetics of primary bilateral macronodular adrenal hyperplasia: a model for early diagnosis of Cushing's syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11993792" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Preclinical Cushing's syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia with excessive secretion of 18-hydroxydeoxycorticosterone and corticosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28877721" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A case of Adrenocoricotrophic hormone -independent bilateral adrenocortical macronodular hyperplasia concomitant with primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21084398" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinical, biochemical, and molecular characterization of macronodular adrenocortical hyperplasia of the zona reticularis: a new syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966714" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Adrenocorticotropin-independent macronodular adrenal hyperplasia: an uncommon cause of primary adrenal hypercortisolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22058378" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : (18)F-FDG-PET/CT imaging of ACTH-independent macronodular adrenocortical hyperplasia (AIMAH) demonstrating increased (18)F-FDG uptake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25766729" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : High 18F-FDG uptake in PMAH correlated with normal expression of Glut1, HK1, HK2, and HK3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6266251" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing's syndrome. Report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6315761" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Macronodular adrenocortical hyperplasia in long-standing Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21598069" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26451908" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Unilateral Adrenalectomy as a First-Line Treatment of Cushing's Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26222757" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Adrenocortical hormone-independent adrenal hyperplasia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30033041" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Advances in the medical treatment of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8977945" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cushing's syndrome due to autonomous macronodular adrenal hyperplasia: long-term follow-up after unilateral adrenalectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834434" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Is unilateral adrenalectomy an alternative treatment for ACTH-independent macronodular adrenal hyperplasia?: Long-term follow-up of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18214589" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal hyperplasia (AIMAH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23592061" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The role of unilateral adrenalectomy in corticotropin-independent bilateral adrenocortical hyperplasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30844071" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18074172" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The clinical conundrum of corticotropin-independent autonomous cortisol secretion in patients with bilateral adrenal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28246963" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Posterior retroperitoneoscopic adrenal surgery for clinical and subclinical Cushing's syndrome in patients with bilateral adrenal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32724871" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A New Insight into the Surgical Treatment of Primary Macronodular Adrenal Hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24795253" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25238207" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21252250" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Integrated genomic analysis of nodular tissue in macronodular adrenocortical hyperplasia: progression of tumorigenesis in a disorder associated with multiple benign lesions.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
